Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

76 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. Karapetis CS, et al. Among authors: shapiro jd. N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385. N Engl J Med. 2008. PMID: 18946061 Clinical Trial.
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.
Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ. Au HJ, et al. Among authors: shapiro jd. J Clin Oncol. 2009 Apr 10;27(11):1822-8. doi: 10.1200/JCO.2008.19.6048. Epub 2009 Mar 9. J Clin Oncol. 2009. PMID: 19273701 Clinical Trial.
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008.
Price TJ, Tebbutt NC, Karapetis CS, Segelov E, Pavlakis N, Cunningham D, Sobrero AF, Haller DG, Shapiro JD. Price TJ, et al. Among authors: shapiro jd. Clin Colorectal Cancer. 2010 Jan;9(1):8-14. doi: 10.3816/CCC.2010.n.001. Clin Colorectal Cancer. 2010. PMID: 20100683 Review.
Management of advanced gastric cancer.
Price TJ, Shapiro JD, Segelov E, Karapetis CS, Pavlakis N, Van Cutsem E, Shah MA, Kang YK, Tebbutt NC. Price TJ, et al. Among authors: shapiro jd. Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):199-208; quiz 209. doi: 10.1586/egh.11.103. Expert Rev Gastroenterol Hepatol. 2012. PMID: 22375525 Review.
Current opinion on optimal treatment for colorectal cancer.
Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, Karapetis CS, Pavlakis N, Sobrero AF, Cunningham D, Shapiro JD. Price TJ, et al. Among authors: shapiro jd. Expert Rev Anticancer Ther. 2013 May;13(5):597-611. doi: 10.1586/era.13.37. Expert Rev Anticancer Ther. 2013. PMID: 23617351 Review.
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ. Siu LL, et al. Among authors: shapiro jd. J Clin Oncol. 2013 Jul 1;31(19):2477-84. doi: 10.1200/JCO.2012.46.0543. Epub 2013 May 20. J Clin Oncol. 2013. PMID: 23690424 Clinical Trial.
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.
Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ; NCIC Clinical Trials Group; Australasian Gastrointestinal Trials Group. Ringash J, et al. Among authors: shapiro jd. Cancer. 2014 Jan 15;120(2):181-9. doi: 10.1002/cncr.28410. Epub 2013 Oct 11. Cancer. 2014. PMID: 24127364 Clinical Trial.
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.
Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group. Karapetis CS, et al. Among authors: shapiro jd. Clin Cancer Res. 2014 Feb 1;20(3):744-53. doi: 10.1158/1078-0432.CCR-13-0606. Epub 2013 Nov 11. Clin Cancer Res. 2014. PMID: 24218517 Clinical Trial.
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.
Price TJ, Segelov E, Burge M, Haller DG, Tebbutt NC, Karapetis CS, Punt CJ, Pavlakis N, Arnold D, Gibbs P, Shapiro JD. Price TJ, et al. Among authors: shapiro jd. Expert Rev Anticancer Ther. 2014 Dec;14(12):1477-93. doi: 10.1586/14737140.2014.949678. Epub 2014 Aug 20. Expert Rev Anticancer Ther. 2014. PMID: 25138900 Review.
Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia.
Turner NH, Wong HL, Field K, Wong R, Shapiro J, Yip D, Nott L, Tie J, Kosmider S, Tran B, Desai J, McKendrick J, Zimet A, Richardson G, Iddawela M, Gibbs P. Turner NH, et al. Asia Pac J Clin Oncol. 2015 Sep;11(3):262-71. doi: 10.1111/ajco.12355. Epub 2015 Apr 14. Asia Pac J Clin Oncol. 2015. PMID: 25871458
76 results